JP2012087150A5 - - Google Patents

Download PDF

Info

Publication number
JP2012087150A5
JP2012087150A5 JP2012020558A JP2012020558A JP2012087150A5 JP 2012087150 A5 JP2012087150 A5 JP 2012087150A5 JP 2012020558 A JP2012020558 A JP 2012020558A JP 2012020558 A JP2012020558 A JP 2012020558A JP 2012087150 A5 JP2012087150 A5 JP 2012087150A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antigen
exogenous
exogenous antigen
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012020558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012087150A (ja
JP5930742B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012087150A publication Critical patent/JP2012087150A/ja
Publication of JP2012087150A5 publication Critical patent/JP2012087150A5/ja
Application granted granted Critical
Publication of JP5930742B2 publication Critical patent/JP5930742B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012020558A 2000-10-27 2012-02-02 免疫抑制された患者のためのワクチン免疫療法 Expired - Lifetime JP5930742B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24391200P 2000-10-27 2000-10-27
US60/243,912 2000-10-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008331616A Division JP2009102372A (ja) 2000-10-27 2008-12-25 免疫抑制された患者のためのワクチン免疫療法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013014029A Division JP5963688B2 (ja) 2000-10-27 2013-01-29 免疫抑制された患者のためのワクチン免疫療法
JP2015089246A Division JP2015155446A (ja) 2000-10-27 2015-04-24 免疫抑制された患者のためのワクチン免疫療法

Publications (3)

Publication Number Publication Date
JP2012087150A JP2012087150A (ja) 2012-05-10
JP2012087150A5 true JP2012087150A5 (enExample) 2013-03-21
JP5930742B2 JP5930742B2 (ja) 2016-06-08

Family

ID=22920630

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2002537179A Withdrawn JP2004521867A (ja) 2000-10-27 2001-10-26 免疫抑制された患者のためのワクチン免疫療法
JP2008331616A Withdrawn JP2009102372A (ja) 2000-10-27 2008-12-25 免疫抑制された患者のためのワクチン免疫療法
JP2012020558A Expired - Lifetime JP5930742B2 (ja) 2000-10-27 2012-02-02 免疫抑制された患者のためのワクチン免疫療法
JP2013014029A Expired - Lifetime JP5963688B2 (ja) 2000-10-27 2013-01-29 免疫抑制された患者のためのワクチン免疫療法
JP2015089246A Withdrawn JP2015155446A (ja) 2000-10-27 2015-04-24 免疫抑制された患者のためのワクチン免疫療法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2002537179A Withdrawn JP2004521867A (ja) 2000-10-27 2001-10-26 免疫抑制された患者のためのワクチン免疫療法
JP2008331616A Withdrawn JP2009102372A (ja) 2000-10-27 2008-12-25 免疫抑制された患者のためのワクチン免疫療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013014029A Expired - Lifetime JP5963688B2 (ja) 2000-10-27 2013-01-29 免疫抑制された患者のためのワクチン免疫療法
JP2015089246A Withdrawn JP2015155446A (ja) 2000-10-27 2015-04-24 免疫抑制された患者のためのワクチン免疫療法

Country Status (7)

Country Link
US (8) US6977072B2 (enExample)
EP (1) EP1337149A4 (enExample)
JP (5) JP2004521867A (enExample)
AU (2) AU2002232560A1 (enExample)
CA (2) CA2464228C (enExample)
MX (1) MXPA03003638A (enExample)
WO (1) WO2002034119A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
EP1337149A4 (en) 2000-10-27 2005-10-12 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
DE10139965B4 (de) * 2001-08-14 2005-12-29 Biotest Ag Gammasterilisierbares Kulturmedium zum Nachweis von Hefen und Pilzen
CA2498591A1 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20050002899A1 (en) * 2003-07-03 2005-01-06 Eyal Talor Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
US7342268B2 (en) * 2004-12-23 2008-03-11 International Business Machines Corporation CMOS imager with Cu wiring and method of eliminating high reflectivity interfaces therefrom
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture
WO2007149381A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
US20080131396A1 (en) * 2006-12-04 2008-06-05 Cel-Sci Corp. Method for altering the CD4/CD8 ratio and the mononuclear cellular infiltrate into a tumor
AU2008329741B2 (en) * 2007-11-28 2013-09-12 Irx Therapeutics, Inc. Method of increasing immunological effect
DK2276850T5 (da) * 2008-04-14 2013-12-02 Irx Therapeutics Inc Irx-2-modificeret fremstillingsfremgangsmåde
US20110081313A1 (en) * 2008-05-29 2011-04-07 Irx Therapeutics, Inc. Mechanism of action of primary cell derived biologic
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス, インコーポレイテッド ワクチン免疫療法
AU2010328197B2 (en) * 2009-12-08 2015-07-16 Irx Therapeutics, Inc. Method of reversing immune suppression of Langerhans cells
WO2012037551A2 (en) * 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
US11712474B2 (en) * 2019-07-29 2023-08-01 Regen BioPharma, Inc. Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
CN112972669A (zh) * 2021-03-08 2021-06-18 河南道特尔医药科技股份有限公司 一种提高新冠疫苗对特殊人群抗体分泌的动物实验操作方法

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (enExample) 1971-11-19 1975-02-07 Anvar
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) * 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
US4690623A (en) * 1978-05-31 1987-09-01 Karl Eickmann Fluid pumps, fluid motors and devices, which include a coned ring
DE2919592A1 (de) 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
DE3100974A1 (de) 1980-01-18 1982-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente
US4470926A (en) 1980-01-18 1984-09-11 Max-Planck-Gesellschaft zur F/o/ rderung der Wissenschaften e.V. Medicaments containing thymosin alpha 1 fragments and having an immunostimulant action, and fragments of thymosin alpha 1
US4612365A (en) 1980-03-25 1986-09-16 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US4293455A (en) * 1980-04-07 1981-10-06 Rockefeller University N.sup.α -Desacetylthymosinα1 and process
IL62903A0 (en) 1980-05-22 1981-07-31 Deutsches Krebsforsch Method for the production of interferon ii and stimulated clones for the carrying out of the method
US4390623A (en) 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4448879A (en) * 1981-03-26 1984-05-15 Hooper Trading Company High yield process for in vitro production of serum-free and mitogen-free interleukin-2
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4406830A (en) * 1981-04-17 1983-09-27 Shanksville Corporation, N.V. Regulatory glycoprotein for immune response and the use thereof in the production of T-cell growth factor
DE3120912A1 (de) 1981-05-26 1982-12-16 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von p-nitrophenetol
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4504415A (en) * 1983-04-04 1985-03-12 Hoffman-La Roche Inc. Synthesis of thymosin α1 and desacetyl thymosin α1
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4614731A (en) * 1983-09-15 1986-09-30 Hoffmann-La Roche Inc. Peptide having immunopotentiating activity similar to thymosin alpha1
US4659694A (en) * 1983-10-27 1987-04-21 Hoffmann-La Roche Inc. Prothymosin alpha
US4716148A (en) * 1984-08-13 1987-12-29 Hoffman-La Roche Inc. Prothymosin alpha
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5100664A (en) 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US5503841A (en) 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
AU7397887A (en) 1986-05-09 1987-12-01 Sloan-Kettering Institute For Cancer Research Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5376369A (en) 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
SE8801426D0 (sv) 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling
JP2955314B2 (ja) * 1988-10-27 1999-10-04 リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ Il―2含有リポソーム免疫アジュバント
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
IT1238231B (it) 1989-12-18 1993-07-12 Consiglio Nazionale Ricerche Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
JPH07503851A (ja) 1992-02-10 1995-04-27 インターフェロン・サイエンシズ、インコーポレイテッド 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法
US5679356A (en) 1992-07-08 1997-10-21 Schering Corporation Use of GM-CSF as a vaccine adjuvant
CN1094310A (zh) 1992-12-15 1994-11-02 托马斯·C·梅里根 人体免疫缺陷性病毒感染用组合式化学疗法
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
EP0700430B1 (en) 1993-06-04 2005-04-20 The United States of America as Represented by the Secretary of the Navy Methods for selectively stimulating proliferation of t cells
JPH09504000A (ja) * 1993-08-11 1997-04-22 ジェナー テクノロジーズ 前立腺癌ワクチン
CN1044781C (zh) 1994-02-05 1999-08-25 丹东市生物制品免疫技术应用研究中心 复方免疫抗生素
DE4412794A1 (de) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
ATE287270T1 (de) 1994-11-17 2005-02-15 Univ South Florida Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5626838A (en) * 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
JPH11504814A (ja) 1995-05-04 1999-05-11 アメリカ合衆国 Bcl−x▲下l▼タンパク質レベルを調節することによる、t細胞生存の調節法
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
ES2324745T3 (es) 1996-02-21 2009-08-13 Genetic Immunity Kft. Procedimientos y composiciones para la inmunizacion genetica protectora y terapeutica.
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US5849307A (en) 1997-03-26 1998-12-15 The Picower Institute For Medical Research Vaccine adjuvant
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
EP1027453A4 (en) * 1997-10-17 2004-12-01 Univ South Florida METHOD FOR DIAGNOSIS AND MONITORING OF CELLULAR IMMUNE FUNCTIONS
EP0922758B1 (en) * 1997-10-27 2009-04-15 Rockefeller University Methods and compositions for obtaining mature dendritic cells
ATE275421T1 (de) * 1998-02-12 2004-09-15 Wyeth Corp Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
US20050124645A1 (en) * 1998-04-20 2005-06-09 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
EP0974357A1 (en) * 1998-07-16 2000-01-26 Schering-Plough Chemokines as adjuvants of immune response
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
GB9827103D0 (en) 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6350589B1 (en) * 1998-12-31 2002-02-26 Viragen, Inc. Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
GB9903664D0 (en) * 1999-02-17 1999-04-14 Isis Innovation Adjuvant and cell maturation agent
US6667175B1 (en) 1999-06-15 2003-12-23 The Trustees Of Columbia University Generation of antigen specific T suppressor cells for treatment of rejection
US7056503B2 (en) * 1999-08-19 2006-06-06 Regents Of The University Of Michigan Enclosures housing cell-coated supports for treating tumors
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
ES2302726T3 (es) * 2000-02-24 2008-08-01 Invitrogen Corporation Estimulacion y concentracion simultanea de celulas.
CA2409406C (en) * 2000-06-22 2010-09-14 American Cyanamid Company Qs-21 and il-12 as an adjuvant combination
EP1337149A4 (en) 2000-10-27 2005-10-12 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS
US20070154399A1 (en) 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US7182942B2 (en) 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
CA2498591A1 (en) 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
DE10154579A1 (de) * 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
WO2003061566A2 (en) 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
US20040170646A1 (en) 2002-12-13 2004-09-02 Aventis Pasteur, Inc. Production of ALVAC on avian embryonic stem cells
KR101162908B1 (ko) * 2002-12-26 2012-07-06 마운틴 뷰 파마슈티컬즈, 인크. 수용체-결합 활성이 보존된, 사이토카인, 케모카인,성장인자, 폴리펩티드 호르몬 및 이들의 길항제의 중합체접합체
WO2004092212A2 (en) 2003-04-15 2004-10-28 Sanofi Pasteur Limited Tumor antigens bfa5 for prevention and/or treatment of cancer
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
WO2005077048A2 (en) 2004-02-09 2005-08-25 The Johns Hopkins University Immune modulation by regulating expression of the “minor” gene in immune dendritic cells
GB0409799D0 (en) * 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
ES2553133T3 (es) 2004-06-04 2015-12-04 Cel-Sci Corporation Método de modificación de la proporción de CD4/CD8 y del infiltrado celular mononuclear en un tumor
US9750797B2 (en) 2004-06-16 2017-09-05 Virbac Corporation Sustained release vaccine composition
WO2006047515A2 (en) 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
US20070065415A1 (en) 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
EP1996013A4 (en) 2005-09-21 2010-03-10 Dask Technologies Llc METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES
KR20080109717A (ko) 2005-12-08 2008-12-17 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한조성물 및 방법
WO2007130826A2 (en) 2006-05-04 2007-11-15 Ge Healthcare Bio-Sciences Ab Separation of cells
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
KR20100025514A (ko) 2007-04-25 2010-03-09 임뮤룩스, 인코포레이티드 Nkt 활성화제,cd40 효능제 및 임의의 항원의 애주번트 조합물 및 상승적인 세포 면역성의 유도에 의한 용도
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
AU2008329741B2 (en) 2007-11-28 2013-09-12 Irx Therapeutics, Inc. Method of increasing immunological effect
DK2276850T5 (da) * 2008-04-14 2013-12-02 Irx Therapeutics Inc Irx-2-modificeret fremstillingsfremgangsmåde
US20110081313A1 (en) * 2008-05-29 2011-04-07 Irx Therapeutics, Inc. Mechanism of action of primary cell derived biologic
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス, インコーポレイテッド ワクチン免疫療法
AU2010328197B2 (en) 2009-12-08 2015-07-16 Irx Therapeutics, Inc. Method of reversing immune suppression of Langerhans cells
WO2012037551A2 (en) 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine

Similar Documents

Publication Publication Date Title
JP2012087150A5 (enExample)
JP2013075922A5 (enExample)
JP2013509429A5 (enExample)
MX2013004817A (es) Enfermedad inflamatoria.
JP2015524462A5 (enExample)
CY1123739T1 (el) Αντισωματα anti-cd38
JP2013241424A5 (enExample)
CN113748114A (zh) 一种喹唑啉化合物及其在医药上的应用
MX2021001762A (es) Metodo y composicion para estimular la respuesta inmunitaria.
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
JP2015528491A5 (enExample)
JP2014521735A5 (enExample)
EP4382164A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX2018013623A (es) Derivados de n-acildipeptido y sus usos.
JP2015533376A5 (enExample)
NO20064781L (no) Fremgangsmater og adjuvanser for a forbedre immunresponser mot vaksiner og fremgangsmater for anvendelse
JP2013537532A5 (enExample)
JP2015522522A5 (enExample)
JP2015527374A5 (enExample)
IL275145B1 (en) Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
RU2010103781A (ru) Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан
JP2012506394A5 (enExample)
JP2016530291A5 (enExample)
JP2015507020A5 (enExample)
RU2016112257A (ru) Композиция для лечения гипертензии и/или фиброза